MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out
GESCHÄTZT50 % SICHERHEITClinicalTrials.gov[1] lists 2027-10-18 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Merck & Co.'s phase 3 trial of MK-8527 in human immunodeficiency virus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,580 participants. Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
1.00